- Home
- KFS vs LUNG Comparison
KFS vs LUNG Comparison
Compare KFS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- LUNG
- Stock Information
- Founded
- KFS 1989
- LUNG 1995
- Country
- KFS United States
- LUNG United States
- Employees
- KFS N/A
- LUNG N/A
- Industry
- KFS Property-Casualty Insurers
- LUNG Industrial Specialties
- Sector
- KFS Finance
- LUNG Health Care
- Exchange
- KFS Nasdaq
- LUNG Nasdaq
- Market Cap
- KFS 234.2M
- LUNG 243.2M
- IPO Year
- KFS 1996
- LUNG 2020
- Fundamental
- Price
- KFS $8.46
- LUNG $6.16
- Analyst Decision
- KFS
- LUNG Buy
- Analyst Count
- KFS 0
- LUNG 6
- Target Price
- KFS N/A
- LUNG $11.92
- AVG Volume (30 Days)
- KFS 63.9K
- LUNG 236.5K
- Earning Date
- KFS 11-06-2024
- LUNG 02-19-2025
- Dividend Yield
- KFS N/A
- LUNG N/A
- EPS Growth
- KFS N/A
- LUNG N/A
- EPS
- KFS N/A
- LUNG N/A
- Revenue
- KFS $108,627,000.00
- LUNG $79,302,000.00
- Revenue This Year
- KFS N/A
- LUNG $22.26
- Revenue Next Year
- KFS N/A
- LUNG $18.72
- P/E Ratio
- KFS N/A
- LUNG N/A
- Revenue Growth
- KFS 2.02
- LUNG 22.34
- 52 Week Low
- KFS $7.60
- LUNG $5.46
- 52 Week High
- KFS $9.58
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- KFS 44.83
- LUNG 45.69
- Support Level
- KFS $8.33
- LUNG $5.72
- Resistance Level
- KFS $8.75
- LUNG $6.31
- Average True Range (ATR)
- KFS 0.28
- LUNG 0.37
- MACD
- KFS -0.00
- LUNG 0.00
- Stochastic Oscillator
- KFS 41.67
- LUNG 37.29
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.